A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Trial Profile

A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs BAY 1093884 (Primary) ; BAY 1093884 (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 09 Mar 2018 Planned End Date changed from 31 Jul 2018 to 6 Aug 2018.
    • 09 Mar 2018 Planned primary completion date changed from 15 Jun 2018 to 25 Jun 2018.
    • 09 Jan 2018 Planned number of patients changed from 38 to 32.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top